Trial Profile

Immunogenicity and Safety of IndoVac as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of Age

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SARS CoV 2 vaccine-PT Bio Farma (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Sponsors PT Bio Farma

Most Recent Events

03 Jun 2025 Status changed from active, no longer recruiting to completed.
16 May 2023 Planned primary completion date changed from 31 Mar 2023 to 31 May 2023.
16 May 2023 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com